# Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation

> **NCT05489523** · PHASE4 · RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 25 (estimated)

## Conditions studied

- Transthyretin Cardiac Amyloidosis

## Interventions

- **DRUG:** Tafamidis 61 MG

## Key facts

- **NCT ID:** NCT05489523
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-01
- **Primary completion:** 2026-05-01
- **Final completion:** 2026-05-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05489523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05489523, "Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05489523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*